LEXINGTON, Mass. (PRWEB)
July 09, 2020

Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced the hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson will join Sentien’s executive team and oversee the clinical development of Sentien’s lead product, SBI-101. Dr. Nissenson serves as an Emeritus Professor of Medicine at the David Geffen School of Medicine at the University of California Los Angeles, Emeritus Chief Medical Officer of DaVita Kidney Care, and a member of the Board of Directors of Angion Biomedica Corp and Rockwell Medical, Inc.

“Dr. Nissenson is an industry leader and renowned authority on kidney disease,” said Sentien CEO, Brian Miller. “His executive experience will be critical for Sentien as we continue development of SBI-101 in patients with acute kidney injury and advance our novel cell therapy platform to treat other conditions characterized by systemic inflammation, including COVID-19.” “I’ve known Allen throughout his career and he is uniquely qualified to provide the clinical, policy and regulatory leadership that will guide Sentien through its next stage of growth,” added Sentien Executive Chairman, Rich Ganz. “He will be a valued addition to the executive team, and I look forward to the opportunity to work with him closely.”

“I am very excited to be joining Sentien Biotechnologies as Chief Medical Officer,” said Dr. Nissenson. “Sentien’s technology has the potential to transform the treatment of kidney disease as well as that of other systemic inflammatory conditions. I look forward to leading the clinical development efforts to bring this innovative treatment to patients with currently few therapeutic options.”

In addition to his current roles, Dr. Nissenson is the immediate past Chair of Kidney Care Partners, immediate past Co-Chair of the Kidney Care Quality Alliance, and he served as Director of the Dialysis Program and Associate Dean at the David Geffen School of Medicine at UCLA. He is a former President of the Renal Physicians Association and current member of the Government Affairs Committee. Dr. Nissenson also previously served as President of the Southern California End-Stage Renal Disease Network, as well as Chair of the Medical Review Board. Dr. Nissenson served for a year in Washington, D.C. as a Robert Wood Johnson Health Policy Fellow, working in the U.S. Senate with the late Senator Paul Wellstone. He earned his M.D. from Northwestern University Medical School.

About Sentien Biotechnologies

Sentien Biotechnologies, Inc. is a privately-held, clinical-stage company developing novel ex-vivo cell therapy applications to treat conditions caused by systemic, immune-mediated inflammation. Sentien’s lead product, SBI-101, integrates allogeneic mesenchymal stromal cells (MSCs) within an extracorporeal, hollow-fiber device. By immobilizing MSCs within a blood-filtration device, SBI-101 allows for prolonged exposure of patient blood to the MSCs, resulting in the dynamic delivery of MSC-secreted factors at doses that are unattainable by direct injection.

SBI-101 is being evaluated in a Phase 1b/2a study in subjects with dialysis-requiring acute kidney injury (AKI-D). An interim readout from the clinical study provides evidence of anti-inflammatory and wound healing effects consistent with the SBI-101 therapeutic hypothesis. Building on this therapeutic hypothesis, SBI-101 is being pursued in COVID-19 patients suffering from severe systemic inflammation.

Sentien’s technology can be applied to additional systemic inflammatory indications in both acute and chronic diseases, focusing on complex conditions where single-factor agents have not been effective.

For more information, please visit http://www.sentienbiotech.com.

Share article on social media or email: